Search 

Since 2001, Fusion Antibodies has been dedicated to the discovery and early development of antibodies to help bring about a positive change in the healthcare industry. We offer a complete range of antibody-related services in Discovery, Engineering and Supply and have guided hundreds of projects through critical preclinical stages. Fifteen of our client’s projects have advanced to clinical stages, some as far as Phase II.

We deliver a superior service for the development of antibodies by beginning each project with the end in mind. Our scientists are experts in early stage discovery of biologics.

We offer this personalised service because we know that investment at the early stages saves not only millions of dollars but also months, even years of time, on projects that go awry at later stages of development. Through our vast experience we have developed a number of our own proprietary platforms for Antibody Humanization (CRX™), Affinity Maturation (RAMP™) and Developability optimisation (ADD™).

Fusion Antibodies is a publicly held company, trading on the London Stock Exchange (LSE FAB.L) with headquarters in Belfast, Northern Ireland.

Karma Oncology is an oncology specialized, well-established unique clinical development company which was incorporated in 2012. Our flexibility and agility allow us to perform individual tasks on a clinical trial or provide full service. Our services include but are not limited to, clinical development planning, protocol preparation, site selection, regulatory submissions and project management. Quality is critical and to that end, we maintain the same team through the lifecycle of the study. Meeting timelines is as important as quality and we work closely with sponsors to ensure we work to their timelines – irrespective of time zones. Experience is critical to success and the Karma Oncology team has unmatched experience in phases I – III oncology trials, i.e. from first in man through pivotal registration studies and in a wide variety of types of cancer and treatment types.

Our team of professionals are known for their exceptional and extensive experience. Such experience includes both solid tumours and haematological malignancies as well as novel immunotherapy treatments such as autologous cell therapy and CAR-T therapy.

Headquartered in Scotland with teams across Europe and the US we work with sponsors around the globe. In late 2017 we established a cardiology focussed sister company, Karma Cardiology, which has the same business model and services, but with a team of cardiology focussed professionals.

Microbiotica is transforming personalised medicine with leading microbiome science, identifying gut bacteria linked to patient phenotype with unprecedented precision for the discovery of novel microbiome-based medicines and biomarkers of drug response.

Microbiotica was spun out of Trevor Lawley’s Lab at the Wellcome Sanger Institute and is founded on a unique pipeline for culturing and genomically characterising the entirety of the bacteria in the human gut for the first time. It has the world’s largest microbiome genome database and culture collection, a suite of translational in vitro and animal models, and state of the art bioinformatics and AI. The company has a focus on IBD and Immuno-Oncology, and a program in C. difficile which is spearheading innovation in development of live bacterial products.

Midatech Pharma is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines.
Driven by a team of scientists, engineers, and pharmaceutical development specialists, and led by an experienced management team, Midatech is progressing a pipeline of differentiated therapeutics in areas of high unmet need for the benefit of patients

Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular conversion (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020).

The platforms, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and culture medium conditions required to produce any target cell type from any source cell type. The platform can be used to enhance existing stem-cell forward reprogramming methods or can bypass development pathways altogether, affecting a direct transdifferentiation between a mature cell type to another mature cell type.

Mogrify is applying its proprietary and award-winning platforms to engineer an evergreen and scalable source of cell types that exhibit efficacy and safety profiles necessary to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies for indications of high unmet clinical need in hematological, immunological, ophthalmological and other disease areas.

The Clinical Research Network supports research to make patients, and the NHS, better.



We are part of the National Institute for Health Research - which is the clinical research arm of the National Health Service in England.



We provide the practical support that academic and commercial life-sciences industry researchers need to make studies happen in the NHS, so that more research can take place, and more patients can take part.



This practical support includes:



Reducing the "red-tape"​ around setting up a clinical study

Funding the people and facilities needed to carry out research "on the ground"​, so research activity does not drain resources

Helping researchers to identify suitable NHS sites, and recruit patients to take part in research studies

Advising researchers on how to make their study "work"​ in the NHS environment

OBN is the membership organisation supporting and bringing together the UK's emerging life science companies, corporate partners and investors. Our 380+ member companies are located across the Golden Triangle and beyond, and benefit from our networking, partnering, purchasing, advising, and advocacy activities. OBN organises BioTrinity - Europe's Leading Investment and Biopartnering Conference attracting over 1000 delegates (April 23-25, 2018).

Oncimmune is a biotech company that specialises in blood tests and services that make use of the immune system. The EarlyCDT blood tests can detect cancer in the earliest stages when the body’s immune system is trying to fight it. The Company’s understanding of the immune system also means they’re able to work closely with pharmaceutical companies to ensure treatments, such as immunotherapy, are as effective and safe as possible.

EarlyCDT Lung is the world’s most thoroughly validated blood test for the detection of lung cancer and requires only a small volume of blood which can be taken using a test in the home or community setting as well as a doctor’s surgery. Shown to detect lung cancer on average four years earlier compared to current standard clinical diagnosis, EarlyCDT Lung can also provide an effective assessment of cancer risk in indeterminate pulmonary nodules (IPNs).